Cranbrook Wealth Management’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-169
Closed -$2.29K – 399
2026
Q2
$2.29K Hold
169
– – ﹤0.01% 374
2026
Q1
$1.01K Hold
169
– – ﹤0.01% 371
2025
Q4
$1.21K Hold
169
– – ﹤0.01% 386
2025
Q3
$1.8K Hold
169
– – ﹤0.01% 371
2025
Q2
$1.64K Sell
169
-10
-6% -$103 ﹤0.01% 375
2025
Q1
$2.67K Sell
179
-1
-0.6% -$15 ﹤0.01% 357
2024
Q4
$2.69K Hold
180
– – ﹤0.01% 337
2024
Q3
$3.44K Buy
180
+1
+0.6% +$21 ﹤0.01% 314
2024
Q2
$3.71K Hold
179
– – ﹤0.01% 279
2024
Q1
$3.37K Hold
179
– – ﹤0.01% 263
2023
Q4
$2.58K Buy
179
+10
+6% +$136 ﹤0.01% 277
2023
Q3
$2.93K Sell
169
-16
-9% -$334 ﹤0.01% 265
2023
Q2
$3.85K Hold
185
– – ﹤0.01% 260
2023
Q1
$4.35K Hold
185
– – ﹤0.01% 261
2022
Q4
$5.17K Hold
185
– – ﹤0.01% 248
2022
Q3
$4K Hold
185
– – ﹤0.01% 276
2022
Q2
$6K Hold
185
– – ﹤0.01% 264
2022
Q1
$7K Hold
185
– – ﹤0.01% 293
2021
Q4
$6K Hold
185
– – ﹤0.01% 315
2021
Q3
$6K Hold
185
– – ﹤0.01% 327
2021
Q2
$6K Sell
185
-18
-9% -$593 ﹤0.01% 304

Other funds holding OGN

Cranbrook Wealth Management's OGN Position: Q3 2026 in Review

Cranbrook Wealth Management sold out of Organon & Co (OGN) in Q3 2026, closing a stake of 169 shares — an estimated $2.29K sold.

Cranbrook Wealth Management first reported a position in OGN in Q2 2021 and held it in 21 quarters. The position peaked at $7K in Q1 2022. 608 funds tracked by Wall St. Rank hold OGN as of Q3 2026.

  • Cranbrook Wealth Management reported no remaining Organon & Co position as of Q3 2026 after selling out during the quarter.
  • Cranbrook Wealth Management sold 169 Organon & Co shares in Q3 2026, an estimated $2.29K.
  • Cranbrook Wealth Management first reported a position in Organon & Co in Q2 2021 and held it in 21 quarters.
  • Cranbrook Wealth Management's Organon & Co position peaked at $7K in Q1 2022.
  • 608 funds tracked by Wall St. Rank held Organon & Co as of Q3 2026.

Based on Cranbrook Wealth Management's 13F filing for Q3 2026, filed 28 Oct 2026.